HER2-positive BC (triple positive on immunohistochemical analysis or gene amplification by fluorescence in situ hybridization–positive as determined by the local institution) confirmed in the primary lesion(s) (in the case of bilateral BC, both right and left lesions) or in the target metastatic lesion(s). Here, ERBB2 is linked to breast cancer.